Compare LXFR & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LXFR | XFOR |
|---|---|---|
| Founded | 1898 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 322.5M | 332.3M |
| IPO Year | 2012 | N/A |
| Metric | LXFR | XFOR |
|---|---|---|
| Price | $13.03 | $3.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $34.67 |
| AVG Volume (30 Days) | 93.1K | ★ 546.4K |
| Earning Date | 10-28-2025 | 11-05-2025 |
| Dividend Yield | ★ 4.05% | N/A |
| EPS Growth | ★ 55.43 | N/A |
| EPS | ★ 0.53 | N/A |
| Revenue | ★ $397,300,000.00 | $33,979,000.00 |
| Revenue This Year | $0.62 | $1,307.51 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.39 | ★ N/A |
| Revenue Growth | 3.36 | ★ 2925.74 |
| 52 Week Low | $9.41 | $1.35 |
| 52 Week High | $14.96 | $26.83 |
| Indicator | LXFR | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 60.35 | 55.94 |
| Support Level | $12.35 | $3.05 |
| Resistance Level | $12.58 | $3.90 |
| Average True Range (ATR) | 0.34 | 0.25 |
| MACD | 0.15 | -0.04 |
| Stochastic Oscillator | 91.72 | 88.24 |
Luxfer Holdings PLC is a manufacturer industrial company innovating niche applications in materials engineering. It focuses on value creation by using its broad array of technical know-how and proprietary technologies to help create a safe, clean, and energy-efficient world. Luxfer's high-performance materials, components, and high-pressure gas containment devices are used in defense, first response and healthcare, transportation, and general industrial applications. It focuses on product lines related to magnesium alloys, zirconium chemicals, and carbon composites. Its segments are Elektron, Gas Cylinders, and Graphic Arts. It generates the majority of its revenue from Elektron and as well as Gas Cylinders.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.